Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

Ginkgo Bioworks Holdings reported a 52% increase in total revenue for 2022, reaching $478 million, exceeding guidance. The company added 59 new Cell Programs, marking 90% growth. Despite this, fourth-quarter revenue fell 34% to $98 million due to reduced COVID-19 testing services. Biosecurity revenue for 2022 was $334 million, up 66%. However, a loss from operations totaled $(2.2) billion, impacted by high stock-based compensation. Ginkgo forecasts at least $275 million in total revenue for 2023, with a plan to add 100 new Cell Programs and expects Biosecurity revenue of at least $100 million.

Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on March 1, 2023, at 4:30 p.m. ET. This event will review the company's business performance for Q4 and the full year ending December 31, 2022. Details regarding the presentation and a link to the webcast will be available on Ginkgo's investor relations website. Investors can submit questions via Twitter or email prior to the event. Ginkgo Bioworks focuses on cell programming and biosecurity solutions across various industries including food, pharmaceuticals, and public health.

Zymtronix and Ginkgo Bioworks (NYSE: DNA) announced a partnership on February 16, 2023, to enhance enzymes for Zymtronix's cell-free biomanufacturing platform. This collaboration aims to optimize enzyme production for food, agriculture, cosmetics, and pharmaceuticals. Zymtronix's technology addresses challenges in traditional biocatalysis, enabling precise production across various sectors. Ginkgo will provide comprehensive support in enzyme engineering and production, facilitating the commercialization of sustainable ingredients. Both companies are eager to extend this partnership for a broader range of products.

Ginkgo Bioworks (NYSE: DNA) has partnered with the Rwanda Biomedical Centre (RBC) to initiate a one-year pathogen monitoring program at Kigali International Airport aimed at identifying new SARS-CoV-2 variants. This initiative, announced on February 15, 2023, involves monitoring wastewater samples from incoming flights and anonymous nasal swabs from international travelers, providing essential public health data to inform global mitigation strategies. The program enhances biosecurity and complements existing initiatives at U.S. airports. Ginkgo will supply support in collection, analysis, and bioinformatics, while RBC will manage operational tasks on-site.

Ginkgo Bioworks (NYSE: DNA) and Bioweg have announced a collaboration aimed at creating sustainable alternatives to synthetic polymers, particularly focusing on bacterial cellulose production. This partnership addresses the rising concerns over microplastic pollution, which significantly impacts health and the environment. Bioweg's biodegradable cellulose products are already being utilized as substitutes for synthetic polymers across various industries, aligning with regulatory efforts to mitigate microplastics. Ginkgo's advanced strain engineering capabilities will support Bioweg in optimizing production and achieving competitive pricing, showcasing a commitment to performance and sustainability.

NAMUH, an infant nutrition company, has partnered with Ginkgo Bioworks (NYSE: DNA) to develop functional oligosaccharides structurally identical to those in human breast milk for infant formula products. NAMUH's technology offers a cost-effective source of human milk oligosaccharides (HMOs) through yeast fermentation. This collaboration aims to enhance the nutritional quality of infant formulas to better match breast milk, addressing a growing consumer demand for safe and high-quality infant nutrition. The partnership is seen as a significant step in improving infant nutrition products.

Ginkgo Bioworks (NYSE: DNA) has partnered with the Public Health Center of Ukraine's Ministry of Health to launch a pilot program for wastewater-based pathogen monitoring. Announced on January 17, 2023, this initiative aims to provide early warnings for infectious disease outbreaks in Ukraine, particularly amid COVID-19 and ongoing war strains on healthcare. Utilizing its Concentric platform, Ginkgo will implement a biosecurity program to monitor pathogens like SARS-CoV-2. The pilot is set for winter and will deliver continuous data to assist health authorities in decisions to mitigate disease burdens on the population.

Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) have expanded their collaboration with the CDC to enhance the Traveler-based Genomic Surveillance program. The initiative, initially focused on SARS-CoV-2, now includes monitoring for influenza viruses in preparation for the 2023-2024 flu season. This pilot study aims to provide vital insights into viral trends by sampling international travelers at major U.S. airports. The data collected will assist in selecting influenza vaccine viruses and bolster the public health response to seasonal influenza while continuing to track COVID-19 variants.

Ginkgo Bioworks (NYSE: DNA) announced preliminary performance updates for 2022, anticipating total revenue within the range of $460-480 million. The company reported a year-end cash balance of approximately $1.3 billion, enhancing its liquidity amidst economic challenges. Ginkgo expects to add 55-60 new Cell Programs and noted growth in biopharma customer engagement, particularly through the launch of Ginkgo Enzyme Services and the opening of Bioworks7 for mammalian cell engineering. A detailed financial report is set for March 2023.